[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizoaffective\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizoaffective":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100451370","exercise-based-program-for-rehabilitation-of-veterans-with-severe-mental-illness-100451370",false,"NCT05157620","Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness","ESHANTI","Inclusion Criteria:\n\n* Written informed consent;\n* age 18-70 years;\n* DSM-5 diagnosis of\n\n  * schizophrenia,\n  * schizoaffective disorder,\n  * bipolar 1 disorder,\n* DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder including those with a co-morbid\n\n  * alcohol use disorder or substance use disorder;\n  * clinically stable;\n* clinical global impression-severity (CGI-S) scores mild to moderately ill\n\nExclusion Criteria:\n\n* Unable to provide written informed consent;\n* intellectual disability (i.e., severe enough to impact understanding of yoga-based exercises) based on chart or IQ\\\u003C80 on the Wechslet Abbreviated Scale of Intelligence-II (WASI-II);\n* disability or illness precluding yoga-based exercises or wellness lifestyle program, e.g.,\n\n  * current or recent angina (\\\u003C6 months),\n  * history of myocardial infarction in the past year (unless permission is obtained from the primary care physician),\n  * uncontrolled hypertension or hypotension;\n* neurological illness complicating diagnosis \u002F cognitive evaluation, e.g.,\n\n  * dementia,\n  * stroke or head injury;\n* physical problems that preclude training for yoga-based exercises \u002F wellness lifestyle program, e.g.,\n\n  * severely impaired vision;\n  * ongoing treatment that includes more than one hour per week of relaxation and mind-body based stress reduction strategies related to yoga","ALL","18 Years","70 Years",{"count":20,"type":21},112,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI). The two-arm randomized controlled trial will compare the efficacy of YE compared to the Wellness Lifestyle Program (WLP). Primary outcomes of the study will be self-report and performance-based measures of community functioning, defined in the investigators study as social, leisure, employment, and life skills functioning in the community. Secondary outcomes will include cognition and physical fitness measures.",[27,28,29],"Schizophrenia","Schizoaffective","Bipolar Disorder 1",[31,32,33,34,35,36,37,38],"schizophrenia","psychotic disorders","schizoaffective","bipolar disorder 1","exercise","yoga","community function","quality of life","RECRUITING","2026-06-29",{"date":42,"type":43},"2026-07-01","ACTUAL",{"date":45,"type":43},"2022-10-24",{"date":47,"type":21},"2026-12-31",{"name":49,"class":50},"VA Office of Research and Development","FED",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":51},"100641717","frontal-gamma-coherence-neurofeedback-for-patients-with-schizophrenia-100641717","NCT07659938","Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia","Preliminary Placebo-Controlled Double-Blind Randomized Clinical Trial of Mobile Platform to Improve Memory From Home or Office for Patients With Schizophrenia","Inclusion Criteria:\n\n1. Voluntary informed consent to participate and capacity to consent as measured by the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC1) instrument;\n2. Age 18 to 55;\n3. Meet DSM-5 criteria for a current diagnosis of schizophrenia or schizoaffective disorder based on a SCID-5 interview and available medical record review;\n4. Clinically stable as operationalized by (a) not having been admitted to a psychiatric hospital within the three months prior to assessment, (b) having had no change in antipsychotic medication dosage within four weeks prior to the baseline assessment, and (c) ascertained to be clinically and medically stable by one of the study investigators\n\nExclusion Criteria:\n\n1. Electroconvulsive therapy within six months of the baseline assessment;\n2. Medical conditions that can impact cognition, including self-reported history of seizure disorder; multiple sclerosis; stroke or major vascular disease; HIV\u002FAIDS; brain cancer; prior head injury involving loss of consciousness;\n3. Current (but not past) major depression;\n4. Substance use disorder other than nicotine or caffeine in the past year;\n5. Inability to read or speak English (with corrected vision or hearing if needed);\n6. Unable to adequately see or manually manipulate a smartphone, tablet or other mobile device;\n7. Uncooperativeness with the laboratory assessment protocol leading to missing data;\n8. Color blindness that interferes with assessment;\n9. Testing in the past 6 months on the cognitive measures","55 Years",{"count":61,"type":21},30,[24],"This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia. Thirty participants will be randomly assigned to receive either active neurofeedback or placebo neurofeedback using a study-provided mobile platform. Participants will complete baseline assessments in person at the University of California San Diego, receive training on home use of the neurofeedback platform, and complete twice-weekly 30-minute sessions at home for 12 weeks. Participants will return for midpoint and end-of-treatment assessments to evaluate feasibility, tolerability, cognitive outcomes, and neurophysiological target engagement.",[27,28],[31,66,67,68,69,70,71,72],"working memory","gamma","EEG","neurofeedback","mobile","digital","neurotechnology","NOT_YET_RECRUITING","2026-06-17",{"date":76,"type":43},"2026-06-22",{"date":78,"type":21},"2027-04",{"date":80,"type":21},"2028-06",{"name":82,"class":83},"BioSignal Solutions LLC","INDUSTRY",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100472701","does-tdcs-change-synaptic-density-in-the-brains-of-patients-with-schizophrenia-100472701","NCT05435300","Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia","Inclusion Criteria:\n\nEnrolment in the tDCS-adherence parent study (REB# 103-2018). The parent study inclusion criteria are:\n\n1. Male or female participants of any race or ethnicity\n2. Inpatients or outpatients ≥18 years of age\n3. DSM-V diagnosis of schizophrenia or schizoaffective disorder\n4. Capable of consenting to participate in the research study\n5. On a stable dose of oral antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study.\n\nExclusion Criteria:\n\nThe exclusion criteria for this study will be the same as the parent study (REB 103-2018). The parent study exclusion criteria are:\n\n1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence\n2. Unstable medical or any concomitant major medical or neurological illness, including a history of seizures\n3. Acute suicidal or homicidal ideation\n4. Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item\n5. DSM-V substance dependence (except caffeine, nicotine, and cannabis\u002Fmarijuana) within 1 month of entering the study\n6. Positive urine drug screen except for cannabis\u002Fmarijuana at the screening visit\n7. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)\n8. Pregnancy\n9. Score \\\u003C32 on the Wide Range Achievement Test-III\n\nAdditional exclusion criteria for this companion study are:\n\n1. Unwilling or incapable to consent to the study based on the MacArthur Test of Competence\n2. Exposure to long-acting injectable antipsychotics in the last 6 months\n3. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines\n4. Receiving treatment with medications such as levetiracetam that blocks SV2a binding\n5. Disorders of coagulation or taking anticoagulant medication\n6. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)",{"count":91,"type":21},20,"OBSERVATIONAL","This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia. Synaptic density levels will be measured using a novel positron emission tomography (PET) radiotracer \\[18F\\]SDM-8, which is currently the best-in-class method to quantify synaptic density in humans. This will be a companion study to a parent study by our group examining the effects of tDCS on treatment adherence in schizophrenia (REB #103-2018).",[27,28],[96],"Positron emission tomography","2025-09-18",{"date":99,"type":43},"2025-09-23",{"date":101,"type":43},"2021-09-17",{"date":103,"type":21},"2026-03-31",{"name":105,"class":106},"Centre for Addiction and Mental Health","OTHER"]